Spots Global Cancer Trial Database for Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
Official Title:
Study ID: NCT02845856
Conditions
Study Description
Brief Summary: The aim of this study is the safety and efficacy of Cetuximab plus natural killer(NK) immunotherapy to recurrent non-small cell lung cancer with EGFR mutation.
Detailed Description: By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Cetuximab and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fuda cancer institute in Fuda cancer hospital, Guangzhou, Guangdong, China
Contact Details
Name: Jibing Chen, MD, PhD
Affiliation: Fuda Cancer Hospital, Guangzhou
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
